Engineered immune cells take on childhood autoimmune diseases
NCT ID NCT06792799
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This early-phase study is testing a new treatment called CAR-NK cells (KN5601) in 36 children with autoimmune diseases like lupus and IgA nephropathy. The cells are designed to target and destroy faulty immune cells. Participants also receive chemotherapy to prepare their bodies. The main goals are to see if the treatment is safe and if it can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000
RECRUITINGHangzhou, Zhejiang, 310052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD19/BCMA CAR NK cells (KN5601) with chemotherapy (fludarabine and cyclophosphamide)
What this could lead to
If successful, this could point toward a new treatment option for children with severe autoimmune diseases that don't respond to standard therapies.
What could go wrong
This is a very early (Phase 1) and small trial (36 participants), so results may not apply broadly. There are also risks from the chemotherapy and cell therapy, including serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.